Abstract: The present invention relates to peptides containing guanidine and halogenated biphenyl moieties of the formula (I), and to salts and solvates of each of these peptides and to processes for the preparation thereof, compositions containing them and the uses of such compounds. It has been found that the compounds have a high microbicide activity and are suited to combat resistant bacteria, such as Methicillin-resistant Staphylococcus aureus (MRSA) strains, at very low concentrations.

Abstract: A method for quantifying acetylamantadine in a urine sample comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.

Abstract: The present invention relates to peptidomimetics of the formula (I) or (I)c wherein L1, L2, L3, R1, R2, R3, R4, R5, R6, n, m, Q, X, Z1 and Z2 are defined as mentioned in the description and to salts and solvates of each of these compounds and to processes for the preparation thereof, compositions containing them and the uses of such compounds. It has been found that the compounds have a high microbicide activity and are suited to combat resistant bacteria, such as meticillin-resistant Staphylococcus aureus (MRSA) strains, at very low concentrations.

Abstract: The present invention relates to peptidomimetics of the formula (I) or (I)c wherein L1, L2, L3, R1, R2, R3, R4, R5, R6, n, m, Q, X, Z1 and Z2 are defined as mentioned in the description and to salts and solvates of each of these compounds and to processes for the preparation thereof, compositions containing them and the uses of such compounds. It has been found that the compounds have a high microbicide activity and are suited to combat resistant bacteria, such as meticillin-resistant Staphylococcus aureus (MRSA) strains, at very low concentrations.

Abstract: A method for quantifying acetylamantadine in a urine sample comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.

Abstract: Elevated levels of spermidine/spermine N1-acetyltransferase (SSAT) gene expression expression were observed in breast, prostate and lung cancer cell lines. Elevated levels of SSAT gene expression were verified in tissues from patients with breast, prostate and lung cancer. Elevated SSAT gene expression is elevated in different human cancers and elevated SSAT gene expression may accordingly serve as a companion diagnostic biomarker for detection and monitoring of cancer progression.

Abstract: The present invention relates to peptidomimetics of the formula (I) or (I)c wherein L1, L2, L3, R1, R2, R3, R4, R5, R6, n, m, Q, X, Z1 and Z2 are defined as mentioned in the description and to salts and solvates of each of these compounds and to processes for the preparation thereof, compositions containing them and the uses of such compounds. It has been found that the compounds have a high microbicide activity and are suited to combat resistant bacteria, such as meticillin-resistant Staphylococcus aureus (MRSA) strains, at very low concentrations.

Abstract: An immunological assay detects and quantifies acetylamantadine in the urine or other bodily fluids of a person who has taken a small dose of amantadine. The quantification of acetylamantadine can be used to quantify SSAT activity and elevated SSAT activity is an indication of diseases including, but not limited, to inflammations and cancers.

Abstract: A method for quantifying acetylamantadine in a urine sample comprises eluting acetylamantadine from the urine sample using solid phase extraction and quantifying the acetylamantadine eluted from the urine sample using Raman spectroscopy.

Abstract: An anti-cancer drug compound comprises a spermidine/spermine N1-acetyltransferase antibody. The spermidine/spermine N1-acetyltransferase antibody may be a monoclonal antibody or a polyclonal antibody. A method of treating cancer comprises the use of a spermidine/spermine N1-acetyltransferase antibody. The spermidine/spermine N1-acetyltransferase antibody may be a monoclonal antibody or a polyclonal antibody.

Abstract: An anti-cancer drug compound comprises an spermidine/spermine N-acetyltransferase substrate. The spermidine/spermine N-acetyltransferase substrate may be a monoamine. The spermidine/spermine N-acetyltransferase substrate may be amantadine, rimantadine, dopamine or L-DOPA. A method of treating cancer comprises the use of an spermidine/spermine N-acetyltransferase substrate to treat cancer. The spermidine/spermine N-acetyltransferase substrate may be a monoamine. The spermidine/spermine N-acetyltransferase substrate may be amantadine, rimantadine, dopamine or L-DOPA.

Abstract: A method for assaying activity of the enzyme spermidine/spermine N1-acetyltransferase (SSAT) uses SSAT substrates by detecting their acetylated forms. SSAT substrates may include rimantadine and tocainide wherein their metabolism occurs in part by the action of the inducible enzyme SSAT to produce the acetylated metabolites N-acetylrimantadine and N-acetyltocainide respectively. SSAT activity may be correlated to pathologic conditions.

Abstract: A method of producing an antibody comprises immunizing a mammal with an amine-derivative of acetylamantadine, immunizing the mammal with acetylamantadine, and producing the antibody from the mammal. The antibody recognizes acetylamantadine but does not recognize amantadine.

Abstract: An alternate process for synthesizing opiate or opioid analgesics and anesthetics, and intermediates thereof is provided. In particular, a process of synthesizing synthetic opiate or opioid compounds such as, for example, remifentanil, carfentanil, sufentanil, fentanyl, and alfentanil are disclosed.

Abstract: A method, system, and computer program product for verifying rule processing for web pages is disclosed. The dynamic content (e.g., the rules) of a website is identified and a key is created for that dynamic content. Users of the site are identified and any dynamic content associated with a particular user is verified as being correct. The web content is ignored so that only the rules themselves are analyzed. The resulting file, stripped of the web content, is used to verify that the rules can be successfully processed for each web user, without needing to access the website.

Abstract: An adaptive predictive playout scheme, based on a Least Mean Square (LMS) prediction algorithm, for packet voice applications. The packets are received and stored in a buffer for playout at a constant draining rate P0, where P0 is determined by the codec used. The latency of the packets in the buffer is controlled by discarding the oldest packet in the buffer when the predicted time interval for receipt of the next incoming packet is less than a draining threshold.

Abstract: After determining a distressed mobile subscriber communication unit 100 is within a communication coverage area (60) of a base transceiver station (BTS) (22), a mobile BTS (55) positioned at a first location (201) uses a rotating directional antenna (46) to force mobile subscriber communication units including the mobile subscriber communication unit (100) to hand off communication. When the mobile BTS (55) detects the subscriber ID associated with the mobile subscriber communication unit (100) during handoff, a first direction of the directional antenna (46) is noted. The same procedure is repeated at another location (202) and a second direction of the directional antenna (46) is noted. A triangulation process using the first and second direction of the directional antenna and the first and second locations (201) and (202), reveal the location (203) of the mobile subscriber communication unit (100).

Abstract: A digital cellular radio communication system having a remote repeater is provided. The communication system includes a central communication site which: transmits and receives signals in a first radio channel assigned according to a cellular communication system channel reuse plan, transmits signals to and receives signals from a cellular communication network unit, and digitally processes received signals for subsequent transmission in the first radio channel or to the cellular communication network unit. The communication system further includes a remote communication site, substantially remotely located from the central communication site, which: receives a signal in either the first radio channel or a second radio channel assigned according to the cellular communication system channel reuse plan, channel shifts the received signal between the first and the second radio channels, and transmits the shifted signal in the other of the first and the second radio channels.